News
The company hopes to push the rare-disease treatment toward FDA approval next year. Four months after ditching its lead drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback